171 results on '"Franchimont, N."'
Search Results
2. AB0518 EFFECT OF LITIFILIMAB ON TYPE I INTERFERON (IFN) BIOMARKERS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) OR CUTANEOUS LUPUS ERYTHEMATOSUS (CLE): RESULT OF THE LILAC PHASE 2 STUDY
3. 590 Litifilimab modulates Type 1 interferon (IFN) biomarkers in patients with cutaneous lupus erythematosus (CLE): Result of the LILAC Part B Phase 2 study
4. PO.4.75 The anti-BDCA2 antibody biib059 improves joint and skin manifestations in patients with SLE and both active arthritis and rash
5. POS0713 BIIB059 EFFICACY IN PARTICIPANTS WITH ACTIVE CUTANEOUS LUPUS ERYTHEMATOSUS (CLE): SUBGROUP ANALYSIS OF PARTICIPANTS ACHIEVING CLEAR/ALMOST CLEAR DISEASE ACTIVITY FROM PART B OF THE TWO-PART PHASE 2 LILAC STUDY
6. POS0184 EFFICACY OF BIIB059 ON SKIN MANIFESTATIONS IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE PHASE 2 LILAC STUDY (PART A)
7. POS0698 BIIB059 DEMONSTRATED A CONSISTENT THERAPEUTIC EFFECT ON SRI-4 RESPONSE ACROSS SUBGROUPS OF PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE LILAC PHASE 2 STUDY
8. POS0699 GREATER REDUCTION IN CLASI-A SCORES ACHIEVED WITH BIIB059 VERSUS PLACEBO INDEPENDENTLY OF DISEASE SEVERITY AT BASELINE
9. Low incidence of fracture maintained with long-term denosumab treatment in women aged ≥75 years with postmenopausal osteoporosis
10. Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk
11. Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions
12. OP0193 BIIB059, A HUMANIZED MONOCLONAL ANTIBODY TARGETING BDCA2 ON PLASMACYTOID DENDRITIC CELLS (PDC), SHOWS DOSE-RELATED EFFICACY IN THE PHASE 2 LILAC STUDY IN PATIENTS (PTS) WITH ACTIVE CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
13. Prevention of postmenopausal bone loss by rectal calcitonin
14. Infliximab and the bone in Crohnʼs disease
15. Increased expression of receptor activator of NF-κB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohnʼs disease patients
16. Rapid improvement of bone metabolism after infliximab treatment in Crohnʼs disease
17. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment
18. Relationship between bone mass density and tensile strength of the skin in women
19. Increased synovial fluid levels of soluble CD23 are associated with an erosive status in rheumatoid arthritis (RA)
20. Endogenous production of specific antibodies does not decrease hypocalcemic response to calcitonin in young rabbits
21. Transforming growth factor-β increases interleukin-6 transcripts in osteoblasts
22. FRI0315 Safety, tolerability, pharmacokinetic and pharmacodynamic effects of biib059, a monoclonal antibody targeting bdca2 following intravenous (IV) and subcutaneous (SC) single or multiple doses administration in healthy volounteers (HV) and subjects with active systemic lupus erythematosus (SLE)
23. 1081 BIIB059, a monoclonal antibody targeting BDCA2, decreases Type I Interferon-related genes transcriptional activity in subjects with systemic lupus erythematosus (SLE) and active cutaneous LE (CLE)
24. 1096 Non-invasive tape sampling reveals a type I interferon RNA signature in cutaneous lupus erythematosus that distinguishes affected from unaffected and healthy volunteer skin
25. EFFECT OF LITIFILIMAB ON TYPE I INTERFERON (IFN) BIOMARKERS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) OR CUTANEOUS LUPUS ERYTHEMATOSUS (CLE): RESULT OF THE LILAC PHASE 2 STUDY.
26. Trauma Type of Non-hip, Non-vertebral Fractures in Postmenopausal Women Being Treated for Osteoporosis in Europe
27. PREVALENT FRACTURES IN POSTMENOPAUSAL WOMEN BEING TREATED FOR OSTEOPOROSIS IN EUROPE: RELATIONSHIP BETWEEN TRAUMA TYPE, TIME RELATIVE TO MENOPAUSE, AND FRACTURE LOCATION
28. SAT0222 BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous le
29. SAT0235 BIIB059, a monoclonal antibody targeting BCDA2 shows safety, tolerability, pharmacokinetics, pharmacodynamics in healthy volunteer subjects
30. 83 Biib059, a monoclonal antibody targeting bdca2, demonstrates evidence of proof of biological activity in subjects with cutaneous lupus
31. 405 Temporal relationship of cutaneous lupus erythematosus and systemic lupus erythematosus: a large, retrospective cohort study
32. RANKL Inhibition With Denosumab Does Not Influence 3-year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk
33. SAT0214 Macrophage Activation and Biglycan as Disease Activity and Diagnostic Biomarkers in Systemic Sclerosis
34. SAT0200 Serum Biomarkers of Collagen Turnover in Early and Late Diffuse Systemic Sclerosis
35. DENOSUMAB (DMAB) TREATMENT FOR 6 YEARS MAINTAINS LOW FRACTURE INCIDENCE IN WOMEN >= 75 YEARS WITH POSTMENOPAUSAL OSTEOPOROSIS (PMO)
36. Relationship Between Changes in Bone Mineral Density and Incidence of Fracture with 6 Years of Denosumab Treatment
37. Low Fracture Incidence Is Maintained in Postmenopausal Women >= 75 Years with Osteoporosis with Long-Term Denosumab Treatment
38. 6 YEARS' DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: FIRST 3 YEARS OF THE FREEDOM EXTENSION
39. DENOSUMAB TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS FOR 6 YEARS: RESULTS FROM THE FIRST 3 YEARS OF THE FREEDOM EXTENSION
40. Six Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Results From the First Three Years of the FREEDOM Extension
41. SAT0342 Treatment of postmenopausal women with osteoporosis for six years with denosumab: Three-year results from the freedom extension
42. Denosumab's dynamic CTX profile is maintained over 6 years of treatment: first 3 years of the FREEDOM extension study
43. Denosumab treatment for 6years in postmenopausal women with osteoporosis: The first 3years of the freedom extension
44. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
45. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.
46. Effect of denosumab on the incidence of nonvertebral fractures in postmenopausal women at increased risk of fracture: A freedom study subanalysis (study sponsored by Amgen Inc)
47. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment
48. P283 INCREASED EXPRESSION OF RANKL, RANK AND OSTEOPROTEGERIN IN INFLAMMATORY BOWEL DISEASES
49. Synovial fluid matrix metalloproteinase‐3 levels are increased in inflammatory arthritides whether erosive or not
50. Interleukin 6 is autoregulated by transcriptional mechanisms in cultures of rat osteoblastic cells.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.